MERTK and neoplasm: To harness the increased expression of MerTK on tumour-associated macrophages (TAMs) in the TME, bispecific antibodies (bsAbs) were generated targeting a tumour-associated antigen (TAA) to generate bispecific macrophage engagers (BiMEs).